Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Apr;23(4):565–570. doi: 10.1128/aac.23.4.565

Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.

W Salzer, P S Pegram Jr, C E McCall
PMCID: PMC184702  PMID: 6222696

Abstract

Moxalactam was used as initial, empirical therapy in 69 patients with a variety of serious bacterial infections, 32% of which were accompanied by bacteremia. Overall, the success rate was 83% and drug-related adverse effects were minimal. The drug was less efficacious in infections caused by aerobic gram-positive pathogens than it was in those caused by gram-negative pathogens. The following gram-positive organisms were associated with special problems during moxalactam therapy: Streptococcus pneumoniae (development of meningitis and a relapse of pneumonia with a more resistant strain), Staphylococcus epidermidis (in vivo emergence of moxalactam resistance, and the enterococci (failure of therapy and a fatal superinfection. Moxalactam performed well in infections caused by most gram-negative organisms, including aminoglycoside-resistant strains, but the previously reported emergence of gram-negative bacillary resistance to moxalactam during therapy was reconfirmed in our series with Serratia marcescens. The use of moxalactam in the treatment of gram-negative meningitis was further supported by a patient with meningitis-ventriculitis caused by Bacteroides fragilis who was cured with moxalactam after failure on chloramphenicol.

Full text

PDF
565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett W. M., Singer I., Golper T., Feig P., Coggins C. J. Guidelines for drug therapy in renal failure. Ann Intern Med. 1977 Jun;86(6):754–783. doi: 10.7326/0003-4819-86-6-754. [DOI] [PubMed] [Google Scholar]
  2. Bodey G. P., Fainstein V., Hinkle A. M. Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother. 1981 Aug;20(2):226–230. doi: 10.1128/aac.20.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fisher J. F., Carter M. J., Parsons J., Rissing J. P. Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli. Antimicrob Agents Chemother. 1981 Feb;19(2):218–221. doi: 10.1128/aac.19.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fu K. P., Neu H. C. The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) 1979 Sep;32(9):909–914. doi: 10.7164/antibiotics.32.909. [DOI] [PubMed] [Google Scholar]
  5. Georgopapadakou N. H., Liu F. Y. Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity. Antimicrob Agents Chemother. 1980 Nov;18(5):834–836. doi: 10.1128/aac.18.5.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hall W. H., Opfer B. J., Gerding D. N. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother. 1980 Feb;17(2):273–279. doi: 10.1128/aac.17.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jones R. N., Fuchs P. C., Sommers H. M., Gavan T. L., Barry A. L., Gerlach E. H. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother. 1980 Apr;17(4):750–756. doi: 10.1128/aac.17.4.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jorgensen J. H., Crawford S. A., Alexander G. A. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1980 Jun;17(6):937–942. doi: 10.1128/aac.17.6.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Landesman S. H., Corrado M. L., Cherubin C. C., Gombert M., Cleri D. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis. Am J Med. 1980 Jul;69(1):92–98. doi: 10.1016/0002-9343(80)90505-7. [DOI] [PubMed] [Google Scholar]
  10. Landesman S. H., Corrado M. L., Shah P. M., Armengaud M., Barza M., Cherubin C. E. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. Am J Med. 1981 Oct;71(4):693–703. doi: 10.1016/0002-9343(81)90240-0. [DOI] [PubMed] [Google Scholar]
  11. Lentino J. R., Rytel M. W., Moore E. Therapy of lower respiratory tract infections with moxalactam. Antimicrob Agents Chemother. 1981 May;19(5):801–806. doi: 10.1128/aac.19.5.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Livingston W. K., Elliott A. M., Dismukes W. E., Avent C. K., Cobbs C. G. Clinical evaluation of moxalactam. Antimicrob Agents Chemother. 1981 Jul;20(1):88–97. doi: 10.1128/aac.20.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  14. Olson D. A., Hoeprich P. D., Nolan S. M., Goldstein E. Successful treatment of gram-negative bacillary meningitis with moxalactam. Ann Intern Med. 1981 Sep;95(3):302–305. doi: 10.7326/0003-4819-95-3-302. [DOI] [PubMed] [Google Scholar]
  15. Platt R., Ehrlich S. L., Afarian J., O'Brien T. F., Pennington J. E., Kass E. H. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother. 1981 Sep;20(3):351–355. doi: 10.1128/aac.20.3.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ward J. I., Moellering R. C., Jr Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother. 1981 Aug;20(2):204–207. doi: 10.1128/aac.20.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Weaver S. S., LeBlanc B. M., Bodey G. P. In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic. Antimicrob Agents Chemother. 1980 Jan;17(1):92–95. doi: 10.1128/aac.17.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yu V. L., Vickers R. M., Zuravleff J. J. Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new). Antimicrob Agents Chemother. 1980 Jan;17(1):96–98. doi: 10.1128/aac.17.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES